- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04277715
Parent Training for Youth With Chronic Symptoms
September 12, 2023 updated by: Yale University
Development of a Parent Training Intervention for Pediatric Patients With Medically Unexplained Symptoms
The purpose of this study is to examine the effects of a parent-only, group-based intervention intended to treat youth with chronic, unexplained medical symptoms such as (but not limited to) chronic fatigue, musculoskeletal pain, headache, and abdominal pain.
Prior to and following the intervention, the child and parent(s) will be asked to complete several questionnaires about their well-being and functioning.
The investigators predict that participation in this intervention will lead to change in relevant outcomes, including youth symptoms and functional impairment, and parenting stress and accommodation of symptoms.
The investigators also predict that this group will be acceptable and feasible for parents.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Yale Child Study Center, Yale University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 15 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Presence of medically unexplained symptoms, including: fibromyalgia, chronic fatigue, chronic Lyme disease, irritable bowel syndrome, musculoskeletal pain, headache, abdominal pain and related bowel dysfunction, perceived cognitive impairment, or other nonspecific symptoms
- Symptoms must have been present for at least 3 months, associated with some degree of impairment (e.g., missing school), and not attributable to a known organic or medical disorder despite adequate evaluation
- Participants must be proficient or fluent in English
- Children must live with their participating parent(s) at least 50% of the time
Exclusion Criteria:
- Presence of a serious medical condition by history, including chronic autoimmune or inflammatory condition
- Lifetime history of a psychotic disorder, bipolar disorder, Autism, or intellectual disability (Note: this criterion applies to child and parent(s))
- Presence of severe emotional or behavioral problems that require a more immediate treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Parent training
Parents of participating children with chronic symptoms will receive the intervention in a virtual group format.
Groups will last 90-minutes and run for 6-8 weeks.
Groups will be co-led by a clinical psychologist and pediatric physician with expertise in child behavioral interventions and medically unexplained symptoms.
|
Parents will learn evidence-based techniques for increasing support and decreasing accommodation of children's chronic symptoms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Client Satisfaction Questionnaire (CSQ-8; Attkisson & Greenfield, 1996)
Time Frame: Post-treatment (6-8 weeks)
|
The CSQ-8 is an 8-item self-report questionnaire that assesses satisfaction with (i.e., acceptability of) services received.
Questions are rated on a response scale of 1("Quite dissatisfied") to 4("very satisfied").
An overall score is calculated by summing the respondent's score for each scale item.
Scores range from 8 to 32, with higher values indicating higher satisfaction with/acceptability of treatment.
|
Post-treatment (6-8 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Disability Inventory (FDI; Kashikar-Zuck et al., 2011)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The FDI is a 15-item rating scale that assesses functional disability (i.e., physical and psycho-social functional impairment) in children and adolescents with chronic pain and related conditions.
The FDI has a parent form and a child/adolescent form.
Items are rated on a scale of 0 ("No trouble") to 4 ("Impossible").
Total scores range from 0-60, with higher scores indicating greater functional disability, categorized as No/Minimal (0-12), Moderate (13-29), and Severe (30) Disability.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Pediatric Quality of Life Inventory (PedsQL; Varni, Seid, & Kurtin, 2001)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The PedsQL is a modular, youth- and parent-report questionnaire assessing health-related quality of life in children and adolescents ages 2 to 18.
The PedsQL Generic Core Scales contain 23-items about quality of life in physical, emotional, social, and school domains.
Response options are on a five-point scale, ranging from 0 ("never") to 4 ("almost always").
Items are summed and higher scores indicate higher well-being.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
The Symptom Impact Questionnaire-Revised (SIQR; Bennett, Friend, Jones, Ward, Han, & Ross, 2009)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The SIQR is used to measure physical function, overall impact of the syndrome, and symptom severity in youth (self- and parent-report).
Respondents are asked to rate items on scales such as "no difficulty" to "very difficult" (physical function), "never" to "always" (impact of the syndrome), or "no pain" to "unbearable pain" (example of symptom severity).
Total scores range from 0 (indicating no symptom impact) to 100 (extreme symptom impact).
A 14% change in scores has been empirically determined to represent minimal clinically significant difference following treatment.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Clinical Global Impression Scale (CGI; National Institutes of Mental Health, 1985)
Time Frame: Pre-treatment; Post-treatment
|
The CGI is a clinician-rated measure that assesses overall severity (CGI-S) and improvement (CGI-I) of child symptoms following treatment.
CGI-S scores range from 1 ("normal, not at all ill") to 7 ("extremely ill").
CGI-I scores of 1 ("very much improved") or 2 ("much improved") indicate a positive treatment response; all other responses (3 "minimally improved" to 7 "very much worse") are considered negative responses to treatment.
|
Pre-treatment; Post-treatment
|
Screen for Child Anxiety Related Emotional Disorders (SCARED; Birmaher, Khetarpal, Brent, Cully, Balach, Kaufman, & Neer, 1997)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The SCARED is a 41-item self- and parent-report questionnaire assessing a range of anxiety symptoms.
It is appropriate for children and adolescents ages 8-18.
Items are rated on a 3-point scale ranging from 0 ("not true or hardly ever true") to 2 ("very true or often true").
Items are summed and total scores above 25 indicate the likely presence of an anxiety disorder.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Children's Depression Inventory (CDI-2; Kovacs, 2011).
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The CDI-2 is a 28-item questionnaire assessing depressive symptoms.
There are child- and parent- report versions.
Respondents are asked to rate symptoms they have experienced (or observed, for parents) over the past two weeks.
Each item contains 3 statements scored in order of increasing severity from 0 to 2. Higher total scores indicate greater depressive symptoms.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Family Accommodation Scale - Anxiety (FASA; Lebowitz et al., 2013; Lebowitz, Marin, & Silverman, 2019)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The FASA is a 13-item parent- and child-report scale that assesses family accommodation of a child's anxiety symptoms.
The FASA asks respondents to rate the frequency of parental accommodation, the participation of parents in child's symptoms, and the changes that parents make in routines and schedules due to child's somatic symptoms.
Items are rated on a 5-point response scale.
Together, these items generate the total accommodation score, with higher scores indicating greater frequency and intensity of accommodation.
One additional item assesses the degree of distress the accommodation causes the parents/child, and 4 additional items assess the short-term, negative consequences of not accommodating.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Parenting Stress Index, 4th Edition, Short-Form (PSI-4-SF; Abidin, 2012)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The PSI-4-SF is a 36-item parent-report scale that assesses three domains of parenting stress, including Parental Distress, Parent-Child Dysfunctional Interaction, and Difficult Child, which combine to form a Total Stress scale.
Items are rated on a 5-point scale ranging from 1 ("strongly disagree") to 5 ("strongly agree"), with higher scores indicating more parenting stress.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
The Client Credibility Questionnaire (CCQ; Borkovec & Nau, 1972)
Time Frame: Following 1st group session (1 week)
|
The CCQ will be used to assess parent expectancies about treatment.
To do so, it will be administered to all parents at the end of the first intervention session, after the treatment rationale has been presented.
Parents will be asked to make ratings using a scale of 0 to 2 (None, Some, A lot) about: (1) how logical the treatment seems; (2) how confident they are the treatment will be successful, and (3) how confident they would be in recommending the treatment to a friend.
|
Following 1st group session (1 week)
|
Inventory of Parent Accommodations of Children's Symptoms (IPACS; Harrison, Peterson, Short, & Wetterneck, 2016)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The ICPACS is a 12-item parent-report measure that assesses the frequency of family accommodation of the child's pain in the past week.
Items are rated on a scale ranging from 1 to 5. It includes three subscales: Modifications, Assistance, and Supportive Behaviors.
An initial validation study indicated high internal consistency for the total scale (Harrison et al., 2016).
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Child's Report of Parental Behavior Inventory (CRPBI; Schludermann & Schludermann, 1988)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The CRPBI is a 30-item scale used to assess current level of perceived parental behaviors, including acceptance and psychological control.
Items are rated on a scale from 1 (Not like…) to 3 (A lot like … my mother).
A higher score indicates higher perceived behaviors.
There is also a parent-report version of this scale (PRPBI).
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Perceived Stress Scale (PSS: Cohen, Kamarck, Mermelstein, 1983)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The PSS is a 14-item scale that assesses perceived stress of life situations in adolescents and adults.
Items are scored on a 5-point scale (0=never to 4=very often).
Higher total scores indicate greater levels of perceived stress.
The PSS has satisfactory reliability and has well-established validity in relation to physiological stress responses and anxiety and depressive disorders.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Child Anxiety Sensitivity Index (CASI; Silverman, Fleisig, Rabian, & Peterson, 1991)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The CASI is an 18-item child self-report measure that assesses the extent to which children interpret anxiety symptoms as having negative physical, mental and social consequences.
The scale has good construct validity, internal consistency and test-retest reliability (Silverman et al., 1991).
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Affective Reactivity Index-Child and Parent versions (ARI-C/P; Stringaris, Goodman, Ferdinando, Razdan, Muhrer, Leibenluft, & Brotman, 2012)
Time Frame: Pre-treatment; Post-treatment; 3-month follow-up
|
The ARI-C/P is a parent- and child report measure that assesses frequency, duration, and threshold of child irritability symptoms over 6 months.
The ARI-C/P contains 6 items that are rated along a 3-point scale (0 = not true, 1 = somewhat true, 2 = certainly true); total scores range from 0-12.
A 7th item, not calculated in the total score, assesses level of general impairment caused by the irritability.
The ARI-C/P has shown satisfactory internal consistency, discriminant validity, and is adequately described by a one-factor solution in confirmatory factor analyses.
|
Pre-treatment; Post-treatment; 3-month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Wendy Silverman, Ph.D., Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 5, 2021
Primary Completion (Actual)
January 31, 2023
Study Completion (Actual)
January 31, 2023
Study Registration Dates
First Submitted
February 17, 2020
First Submitted That Met QC Criteria
February 18, 2020
First Posted (Actual)
February 20, 2020
Study Record Updates
Last Update Posted (Actual)
September 14, 2023
Last Update Submitted That Met QC Criteria
September 12, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000027265
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medically Unexplained Symptoms
-
Radboud University Medical CenterCompletedMedically Unexplained Symptoms | Psychosomatic TherapyNetherlands
-
University of California, Los AngelesActive, not recruiting
-
University of OsloRecruitingMedically Unexplained Symptoms | Sense of CoherenceNorway
-
Philipps University Marburg Medical CenterHarvard Medical School (HMS and HSDM); University of Kaiserslautern-LandauCompletedSomatic Symptom DisorderGermany
-
Karolinska InstitutetCompletedSomatic Symptom DisorderSweden
-
Karolinska InstitutetStockholm UniversityCompletedSomatic Symptom DisorderSweden
-
St. Joseph's Healthcare HamiltonUnknownSomatic Symptom Disorders
-
University Hospital, GrenobleGroupe Hospitalier Mutualiste de GrenobleNot yet recruitingAutoimmune Diseases | Medically Unexplained Symptoms | Hypnosis
-
Basque Health ServiceCarlos III Health InstituteCompleted
-
Shanghai Mental Health CenterNot yet recruiting
Clinical Trials on Parent training
-
Oregon Social Learning CenterNational Institute of Mental Health (NIMH)CompletedChild Welfare | Foster Home CareUnited States
-
San Diego State UniversityNational Institute of Mental Health (NIMH); Oregon Social Learning CenterCompletedBehavior ProblemsUnited States
-
University of Maryland, College ParkNational Institute of Mental Health (NIMH)CompletedDepression | Attention Deficit Disorder With HyperactivityUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedDisruptive Behavior DisordersUnited States
-
Rush University Medical CenterNational Institute of Nursing Research (NINR)Completed
-
Assuta Hospital SystemsTel Aviv UniversityCompleted
-
University of WashingtonCompletedOppositional Defiant DisorderUnited States
-
Kingkaew PajareyaMahidol UniversityCompletedCerebral Palsy | Down's Syndrome | Delayed DevelopmentThailand
-
Oregon Social Learning CenterNational Institute on Drug Abuse (NIDA)CompletedParent Management TrainingUnited States
-
Yale UniversityCompletedAnger | Irritable Mood | Disruptive Behavior | Aggression Childhood | Non-Compliance, PatientUnited States